Search

Background: Chinese and Korean Americans have lower colorectal cancer (CRC) screening rates than other racial/ethnic groups, which may be explained by a low level of CRC knowledge and a high level of misconceptions. Thisstudy explores the role of knowledge in CRC screening among these groups. Methods: Chinese (N=59) and Korean(N=61) Americans older than 50 were recruited from the Washington D.C. Metropolitan area. They completed a detailedsurvey and participated in focus groups to discuss their knowledge on CRC and CRC screening. Seventeen physicians,community leaders, and patient navigators participated in key informant interviews. Using a mixed methods approach,data were analyzed quantitatively and qualitatively. Results: Participants lacked knowledge about CRC and CRCscreening. More than half did not know that screening begins at age 50 and there are several types of tests available.More than 30% thought CRC screening was not necessary if there were no symptoms or there was nothing they coulddo to prevent CRC. Focus group findings suggested understanding about CRC was limited by an inadequate source oflinguistically and culturally relevant health information. For example, many participants considered CRC a westerncondition mainly caused by unhealthy diet. This led to under-estimations about their susceptibility to CRC. Knowledgewas positively associated with self-reported screening. Participants who had higher knowledge scores were more likelyto report ever having had a colonoscopy and confidence in ability to have CRC screening. Conclusions: Mixed-methodsanalysis provides multi-faceted perspectives on CRC knowledge and its influence on screening. Study findings canhelp inform interventions to increase CRC screening among Chinese and Korean Americans.

The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic alterations leading to CRPC may reveal potential vulnerabilities for cancer therapy. Here we find that CUB domain-containing protein 1 (CDCP1), a transmembrane protein that acts as a substrate for SRC family kinases (SFKs), is overexpressed in a subset of CRPC. Notably, CDCP1 cooperates with the loss of the tumor suppressor gene PTEN to promote the emergence of metastatic prostate cancer. Mechanistically, we find that androgens suppress CDCP1 expression and that androgen deprivation in combination with loss of PTEN promotes the upregulation of CDCP1 and the subsequent activation of the SRC/MAPK pathway. Moreover, we demonstrate that anti-CDCP1 immunoliposomes (anti-CDCP1 ILs) loaded with chemotherapy suppress prostate cancer growth when administered in combination with enzalutamide. Thus, our study identifies CDCP1 as a powerful driver of prostate cancer progression and uncovers different potential therapeutic strategies for the treatment of metastatic prostate tumors., Introduction Castration-resistant prostate cancer (CRPC) is the second leading cause of death among men in developed countries (1). Although second-generation androgen-deprivation therapies (ADTs) have been successfully used to treat CRPC, [...]